Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000031212 | SCV001161641 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-06-18 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 0.999563 |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000031212 | SCV000326134 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000465250 | SCV000549302 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-04-24 | criteria provided, single submitter | clinical testing | Based on a multifactorial likelihood algorithm using genetic, in silico, and/or statistical data, this variant has been determined to have a high probability of being pathogenic (PMID: 31131967). For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 30209399). ClinVar contains an entry for this variant (Variation ID: 37631). This variant is also known as IVS17+2T>C. Disruption of this splice site has been observed in individual(s) with breast and/or ovarian cancer (PMID: 25556971, 27914478, 28717669, 29339979, 29446198). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 16 of the BRCA1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). |
Department of Medical Genetics, |
RCV000031212 | SCV000564328 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-07-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000563483 | SCV000660953 | pathogenic | Hereditary cancer-predisposing syndrome | 2018-12-26 | criteria provided, single submitter | clinical testing | The c.5074+2T>C intronic pathogenic mutation results from a T to C substitution two nucleotides after coding exon 15 in the BRCA1 gene. This alteration has been previously reported in multiple patients undergoing genetic testing based on personal and/or family history concerning for hereditary breast and ovarian cancer (HBOC) syndrome (Trujillano D et al. J Mol Diagn. 2015 Mar;17:162-70; Lourenco J et al. Genet Mol Biol. Sao Paulo. 2004;27(4):500-504). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. |
Color Diagnostics, |
RCV000563483 | SCV000683248 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-05-07 | criteria provided, single submitter | clinical testing | This variant causes a T to C nucleotide substitution at the +2 position of intron 16 of the BRCA1 gene. Splice site prediction tools suggest that this variant may have a significant impact on RNA splicing. A study using peripheral blood-derived RNA from a carrier has shown that this variant impacts normal RNA splicing (PMID: 30159786). A viability assay using human haploid cell line has shown that this variant disrupts normal BRCA1 function (PMID: 30209399). This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 25556971, 27914478, 29339979, 30159786, Color internal data). In addition, a multifactorial likelihood model using health history and tumor pathology data have suggested this variant have a high probability of being pathogenic (PMID: 31131967). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Mendelics | RCV000465250 | SCV000839219 | pathogenic | Hereditary breast ovarian cancer syndrome | 2018-07-02 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000031212 | SCV001140493 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV000031212 | SCV002512515 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2021-06-07 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1 very strong, PS4 strong, PM2 moderate |
Baylor Genetics | RCV000031212 | SCV004215175 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-03-31 | criteria provided, single submitter | clinical testing | |
Sharing Clinical Reports Project |
RCV000031212 | SCV000053812 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2009-03-06 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000031212 | SCV000145290 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2002-05-29 | no assertion criteria provided | clinical testing | |
Research Molecular Genetics Laboratory, |
RCV000465250 | SCV000587453 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research | |
Department of Pathology and Laboratory Medicine, |
RCV001353976 | SCV000591567 | pathogenic | Malignant tumor of breast | no assertion criteria provided | clinical testing | ||
Brotman Baty Institute, |
RCV000031212 | SCV001237537 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |